Amalgamated Bank reduced its position in Teladoc Health, Inc. (NYSE:TDOC – Free Report) by 38.4% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,720 shares of the health services provider’s stock after selling 3,567 shares during the quarter. Amalgamated Bank’s holdings in Teladoc Health were worth $56,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of TDOC. Massachusetts Financial Services Co. MA raised its stake in Teladoc Health by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 64,132 shares of the health services provider’s stock worth $627,000 after purchasing an additional 2,153 shares during the period. Federated Hermes Inc. grew its holdings in shares of Teladoc Health by 6.6% during the 2nd quarter. Federated Hermes Inc. now owns 121,654 shares of the health services provider’s stock worth $1,190,000 after purchasing an additional 7,549 shares during the period. American Century Companies Inc. increased its position in Teladoc Health by 31.0% during the 2nd quarter. American Century Companies Inc. now owns 136,351 shares of the health services provider’s stock worth $1,334,000 after purchasing an additional 32,240 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Teladoc Health during the 2nd quarter worth approximately $198,000. Finally, Doheny Asset Management CA purchased a new stake in Teladoc Health during the second quarter worth approximately $46,000. 76.82% of the stock is currently owned by hedge funds and other institutional investors.
Teladoc Health Trading Down 3.5 %
NYSE TDOC opened at $8.86 on Wednesday. The firm’s 50 day moving average price is $7.92 and its two-hundred day moving average price is $10.54. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -6.28 and a beta of 0.90. Teladoc Health, Inc. has a twelve month low of $6.76 and a twelve month high of $22.54. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66.
Insider Activity at Teladoc Health
In other Teladoc Health news, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $88,555.06. Following the completion of the sale, the chief executive officer now directly owns 99,929 shares of the company’s stock, valued at approximately $813,422.06. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CEO Laizer Kornwasser sold 10,879 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the completion of the transaction, the chief executive officer now directly owns 99,929 shares of the company’s stock, valued at $813,422.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Willem Waters sold 6,053 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $49,271.42. Following the completion of the transaction, the chief operating officer now directly owns 74,214 shares of the company’s stock, valued at $604,101.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,377 shares of company stock valued at $438,054. 0.95% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the stock. Oppenheimer reduced their price target on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Needham & Company LLC reiterated a “hold” rating on shares of Teladoc Health in a research report on Thursday, August 1st. Evercore ISI dropped their price target on Teladoc Health from $14.00 to $10.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 9th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a report on Friday, August 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 price objective on shares of Teladoc Health in a report on Tuesday, August 20th. Fifteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.31.
Check Out Our Latest Report on Teladoc Health
Teladoc Health Company Profile
Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.
Further Reading
- Five stocks we like better than Teladoc Health
- What is a support level?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- With Risk Tolerance, One Size Does Not Fit All
- 2 Energy Stocks Fueling the AI Datacenter Boom
- 3 Warren Buffett Stocks to Buy Now
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.